Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1993-12-06
1995-11-28
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
4241361, 4241421, 4241471, 4241501, 4241531, 4352402, 435 7021, 4351722, 43524027, 5303873, 53038815, 5303883, 5303884, A61K 3518, A61K 39395, A61K 3940, A61K 3942
Patent
active
054705703
ABSTRACT:
Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
REFERENCES:
patent: 4433059 (1984-01-01), Chang et al.
patent: 4672044 (1987-06-01), Schreiber
Cornacoff, et al., Journal of Clinical Investigation; vol. 71, pp. 236-247; Issued Feb. 1983.
Edberg et al. Quantitative Analysis of the Binding of Soluble Complement-Fixing Antibody/dsDNA Immune Complexes to CRI on Human Red Cellls. Journal of Immunology, vol. 139, No. 11, pp. 3739-3747. 1987.
Crus. Journal of Immunology, vol. 139, No. 11, pp. 3739-3747. 1987.
Titus, et al. Human K/Natural Killer Cells Targeted with Hetero-Cross-Linked Antibodies Specifically Lyse Tumor Cells in Vitro and Prevent Tumor Growth in Vivo.
Journal of Immunology, vol. 139, No. 9, pp. 3153-3158. 1987.
Karpovsky, et al. Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target cell and Anti-FcY Receptor.
Antibodies. J. Experimental Medicine, vol. 160, pp. 1686-1701 1984.
Taylor et al., "In Vivo Binding and Clearance of Circulating Antigen by Bispecific Heteropolymer-Mediated Binding to Primate Erythrocyte Complement Receptor," J. Immunology 148(8): 2462-2468, 15 Apr. 1992.
Kimberly et al., "In Vivo Handling of Soluble Complement Fixing Ab/dsDNA Immune Complexes In Chimpanzees," J. Clin. Invest. 84:962-970, Sep. 1989.
Reist et al., "Antigens Pre-Bound to the Primate Erythrocyte Complement Receptor Via Crosslinked Bispecific (Monoclonal/Antibody Heteropolymers Are Rapidly Cleared From the Circulation," Eur. J. Immunol 23:3021-3027, 1993.
Labuguen Ronald
Reist Craig
Sutherland William M.
Taylor Ronald P.
Webb Donna
Budens Robert D.
University of Virginia Patent Foundation
LandOfFree
Mammalian primate erythrocyte bound heteropolymerized monoclonal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian primate erythrocyte bound heteropolymerized monoclonal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian primate erythrocyte bound heteropolymerized monoclonal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2011733